What is Vectorious?
Vectorious Medical Technologies operates at the intersection of advanced engineering and clinical cardiology. The company is primarily focused on the development of sophisticated, implantable sensing technologies designed to monitor cardiac function in real-time. By providing continuous, actionable data, Vectorious aims to shift the paradigm of heart failure management from reactive treatment to proactive, personalized care. This technological innovation addresses a significant unmet need in the healthcare market, where chronic cardiovascular conditions remain a leading cause of morbidity and high healthcare expenditure. Through its specialized focus on implantable diagnostics, the company is establishing a new standard for patient-centric monitoring, effectively bridging the gap between clinical intervention and daily patient management.
How much funding has Vectorious raised?
Vectorious has raised a total of $5M across 1 funding round:
Private Equity
$5M
Private Equity (2015): $5M with participation from Global Cardiovascular Innovation Center and RAD BioMed
Key Investors in Vectorious
Global Cardiovascular Innovation Center
A specialized organization dedicated to fostering innovation in cardiovascular health through strategic partnerships and clinical research support.
RAD BioMed
RAD Biomed is the investment arm of the RAD Bynet group, focusing on early-stage ventures in Israel, particularly in the MedTech, HiTech, Health, Technology, and Energy sectors.
What's next for Vectorious?
Looking ahead, the strategic deployment of the $5M will likely center on scaling manufacturing capabilities and advancing multi-center clinical trials. As Vectorious moves deeper into its growth phase, the focus will shift toward securing broader regulatory approvals and establishing strategic partnerships with major healthcare providers. The company's ability to integrate its real-time sensing data into existing hospital information systems will be a key determinant of its long-term market penetration. By maintaining its commitment to rigorous clinical validation and technological precision, Vectorious is well-positioned to disrupt the traditional heart failure treatment model, ultimately improving patient outcomes while reducing the long-term economic burden on healthcare systems.
See full Vectorious company page
